Summary The precise mechanism of fever and flu-like syndrome that occurs in treatment with deoxycytidine analogues remains unclear. This study demonstrated a strong correlation between plasma interleukin 6 levels and fever in treatment with oral (E)-2'-deoxy-2'(fluoromethylene)cytidine. another deoxycytidine analogue.
Gemcitabine. a nucleoside analogue. is a potent inhibitor of ribonucleoside diphosphate reductase. a key enzyme involved in DNA svnthesis and therefore a target for cancer chemotherapy.
Gemcitabine has shown significant anti-tumour activitv arainst several malignancies. and induces neutropenia and flu-like symptoms (Abbruzzese et al. 1991 : Poplin et al. 1992 : Abratt et al. 1994 : O Rourke et al. 1994 : Anderson et al. 1994 . 1996 Howvever. the precise mechanism of fever and flu-like svndrome in treatment ,with gemcitabine remains unclear.
(E)-2'-deoxN--2-(fluoromethvlene cy-tidine (FMdC) synthesized at the Hoechst Marion Roussel Research Institute (Cincinnati. OH. USA) is another new deoxycytidine analogue. As flu-like symptoms were highly suggestive of cytokine release by deoxycytidine analogues. this study was performed to inxestigate cvtokine blood levels in relation to flu-hke symptoms in a phase I trial of oral FMdC administered dailv for 5 consecutive davs.
MATERIALS AND METHODS
Ten patients with non-small-cell lung cancer wvere treated wvith FMdC at doses from 2 to 8 mg m-day-' for 5 days. Heparinized blood samples (3 ml) for the cytokine study v-ere obtained before treatment and at 8 and 24 h after oral administration on days 1 and 5. The blood was centrifuged immediately. and the plasma thus obtained was stored at -20 C until analysis. Cvtokine levels were assayed bv enzyme-linked immunosorbent assay (ELISA) using commercially available kits Correspondence to: N Masuda O. pg ml-'. 0.094 pg ml-' and 50 pg ml-' for IL-2. IL-6 andTNF respectively.
RESULTS
Seven patients suffered from flu-like sy mptoms with high fever and aeneral malaise. The effect of dailN FMdC administration on IL-6 induction in ten patients is demonstrated in Figure 1 . The most striking, findina in this studv w-as that eight of ten patients dex eloped a significant rise in plasma lex els of IL-6 after repeated doses. Before treatment. median 11-6 levels were 6.36 pa ml (range. 1.43-24.8 pa ml-'). A first rise in IL-6 lex els w-as recorded 8 h after oral dosing on day 1. The highest IL-6 concentrations recorded of 375 pa ml' ± 267.15 pa ml"(median + s.d.) occurred 8 h after administration on dax 5. There were no sianificant changes in lex els of IL-1. IL-2 or TNT at any point in the treatment in any of the patients. Furthermore. the time course of IL-6 induction closely paralleled that of fever (Figure 1) .
DISCUSSION
Fever and flu-like sy mptoms are troublesome adx erse reactions in treatment with deoxycytidine analogues. The recent availability of methods to measure blood lexels of most cytokines allows the characterization of the pathophysiology in olved in human diseases. Poplin et al ( 1992 ) first measured the cytokine levels (IL-2 and TNF) in a phase I trial of gemcitabine because the toxicity ,v as Xerv similar to that obserx ed wvith IL-2 therapy. However. neither cvtokine w as detected at any dose level.
This is the first study in patients receix ing oral FMdC. another deoxycy'tidine analogue. on a daily x 5-day schedule to show that eight of ten patients dexeloped a significant rise in plasma levels of IL-6 after repeated doses. The time course of IL-6 induction closely paralleled that of fever (Fiaure 1). These results strongly suggest that IL-6 is at least partly involved in the production of ' Figure 1 Changes in plasma interieukin 6 levels and fever in response to FMdC treatment fever and flu-like symptoms in treatment with a deoxvcvtidine analogue.
